Coronado Biosciences finishes funding, fills executive seats

Coronado Biosciences, a New York-based company focused on oncology drug development, has completed a financing series worth $21.6 million. The funds will be used to develop its acute myelogeous leukemia drug, CNDO-109. The company also announced that Glenn Cooper (executive chairman and acting CEO), Eric Rowinsky (vice chairman) and Gary Gemignani (executive VP, COO and CFO) have joined the company. Coronado release

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.